medigraphic.com
ISSN 1561-2937 (Print)

2014, Number 1

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2014; 20 (1)

Estimation of the cardiovascular risk by means of boards of the World Organi-zation of the Health. Sanitary Area

Armas RNB, de la Noval GR, Dueñas HA, Castillo NJC, Suárez MR, Castillo GA

Language: Spanish
References: 51
Page:
PDF size: 429.86 Kb.


ABSTRACT

Introduction: The cardiovascular illnesses constitute the first cause of death in Cuba. Among the boards to calculate the risk cardiovascular to suffer them is the proposal by the OMS/ISH.
Objective: To determine the global cardiovascular risk according to boards of the OMS/ISH and prevalency of cardiovascular risk factors, in the population of the sanitary area "Heroes del Moncada". Revolution Place. Havana 2011.
Methods: Descriptive study, January to December of 2011 in a sample of population from 40 to 70 years in the area of health men-tioned. 902 persons were studied chosen to the chance, utilizing a simple aleatory study for the patient selection.
Results: They classified as under risk the 86.25% of the individuals; moderated risk a 8.76%; high risk 4.9%; the high risk dominat-ed in men and enlarged with the age. The prevalency of factors of risk found in order descendent was: high LDL-C, hypertrigliceridemy, hypercolesterolemy, arterial Blood presure, habit to smoke, obesity by corporal index of mass HDL-C lowers.
Conclusions: The predominance of the global cardiovascular risk under could be explained by the board of risk utilized.


REFERENCES

  1. World Health Organization. Prevention of Cardiovascu-lar Disease. Guidelines for assessment and manage-ment of cardiovascular risk. Geneva, 2007.

  2. Guía de la ESC/EAS sobre el manejo de las dislipe-mias. Rev Esp Cardiol. 2011; 64:1168.e1-e60.

  3. Ordúñez P, Cooper R, Espinosa A, Iraola M, Bernal JL, La Rosa Y. Enfermedades cardiovasculares en Cuba: determinantes para una epidemia y desafíos para la prevención y control. Rev Cubana Salud Pública. 2005; 31:270-84.

  4. Anuario Estadístico MINSAP 2011. [Internet] Disponi-ble en: http://www.sld.cu/sitios/dne/.

  5. The World Health Report 2002: Reducing risks, Pro-moting Healthy Life. Geneva, World Health Organiza-tion. 2002.

  6. Fourth J. Task Force of the European Society of Cardi-ology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28(19): 25. Dis-ponible en: http://eurheartj.oxfordjournals.org/content/28/19/2375.full

  7. D’Agostino R, Vasan RM, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk pro-file for use in primary care. The Framingham Heart Study. Circulation. 2008; 117:743-53.

  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Educa-tion Program (NCEP) Expert Panel on Detection, OMS.

  9. Prevención de las enfermedades cardiovasculares. Guía de bolsillo para la estimación y el manejo del ries-go cardiovascular. Ginebra 2008. ISBN-978-924 3547282.

  10. Prevención de las enfermedades cardiovasculares. Guía de bolsillo para la estimación y el manejo del ries-go cardiovascular. Ginebra 2008. ISBN-978-924 3547282.

  11. De la Noval R, Dra. Armas N, De la Noval I, Fernández Y, Pupo H, Dueñas A, et al. Estimación del Riesgo Cardiovascular Global en una población del Área de Salud Mártires del Corynthia. La Habana, Cuba. Rev Cubana Cardiol Cir Cardiovasc. 2011; 17:62-68.

  12. Ministerio de Salud Pública. Proyecciones de la salud pública en Cuba para el año 2015. La Habana: Editorial Ciencias Médicas; 2006.

  13. Dirección Municipal de Salud “Plaza de la Revolución”. Análisis de la Situación de Salud 2010. Ciudad de La Habana; 2011.

  14. MINSAP. Guía cubana para la Prevención, Diagnóstico y Tratamiento de la Hipertensión Arterial 2006. Comi-sión Nacional Técnica Asesora del Programa de Hiper-tensión Arterial del MINSAP, Cuba. (Segunda Versión); 2006. Disponible en: www.sld.cu/servicios/hta.

  15. Friedewald WT, LevyRI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Choles-terol in Plasma, Without Use of the Preparative Ultra-centrifuge. Clinical Chemistry. 1972; 18:499-502.

  16. Dueñas A, Armas N, Noval R, Turcios SE, Milián A, Cabalé MB. Riesgo cardiovascular total en los trabaja-dores del Hotel «Meliá Cohíba». Rev Cubana Endocri-nol [revista en Internet]. 2008; 19(1). Consultado enero 2010. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532008000100003&lng=es.

  17. Hippisley-Cox J, Coupland C, Vinogradova Y, Rogson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007; 335:136.

  18. Liao Y, McGee DL, Cooper RD, Sutkowski MBE. How generalizable are coronary risk prediction models? Comparison of Framingham and Two national cohorts. Am Heart J. 1999; 137:837-45.

  19. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framing-ham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286:180-7.

  20. Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart dis-ease mortality based on data from the Glostrup Popula-tion Studies and Framingham Heart Study. Int J Epide-miol. 2002; 31:817-22.

  21. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ. 2007; 176:S1-44.

  22. Padilla S, Roselló M. Riesgo cardiovascular global en la población adulta del área urbana del Cantón Central de Cartago, Costa Rica. Rev. Costarr. Cardiol. 2006; 8:11-7.

  23. Houterman S, Boshuizen HC, Verschuren WM, Giam-paoli S, Nissinen A, Menotti A, et al. Predicting cardio-vascular risk in different European countries. Eur Heart J. 2002; 23:294-300.

  24. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, rela-tive weight and ECG abnormalities to the incidence of major coronary events: final report of the pooling Pro-ject. J Chronic Dis. 1978; 31:201-306.

  25. Stamler J, Wentworth D, Neaton JD, for the MRFIT Re-search Group. Is relationship between serum choles-terol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 22 primary screenees of the Multiple Risk Factor Interven-tion Trial (MRFIT). JAMA. 1986; 256:2823-8.

  26. Keys A, Menottti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med. 1984; 13:141-54.

  27. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987; 257:2176-80.

  28. Toor M, Katchalsky A, Agmon J, Allalouf D. Atheroscle-rosis and related factors in immigrants to Israel. Circula-tion. 1960; 22:265-79.

  29. Kagan A, Harris BR, Winkelstein W Jr, Jonson KG, Kato H, Syme SL, et al. Epidemiologic studies of coro-nary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis. 1974; 27:345-64.

  30. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II: the relationship of reduction in incidence of coronary heart disease to colesterol lowering. JAMA. 1984; 251:351-64.

  31. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, et al. Serum cholesterol in young men and subse-quent cardiovascular disease. N Engl J Med. 1993; 328:313-8.

  32. Stamler J, Daviglus ML, Garside DB, Dyer AR, Green-land P, Neaton JD. Relationship of baseline serum cho-lesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mor-tality and to longevity. JAMA. 2000; 284:311-8.

  33. Third Report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation. 2002; 106:3143.

  34. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Factores de riesgo cardiovascular en la población es-pañola: metaanálisis de estudios transversales. Med Clin (Barc). 2005;124:606-12.

  35. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol con-centration lower risk of ischemic heart disease. BMJ. 1994; 308:367-72.

  36. Marma A, Berry J, Ning H, Persell S, Lloyd-Jones D. Distribution of 10-Year and Lifetime Predicted Risks for Cardiovascular Disease in US Adults: Findings From the National Health and Nutrition Examination Survey 2003 to 2006 .Circ Cardiovasc Qual Outcomes. 2010;3;8-14.

  37. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. Circulation. 1977;55:767-72.

  38. Gordon T, Casteilli WP, Hjortland MC, Kannel WB, Daqber TR. High density lipoprotein as a protective fac-tor against coronary heart disease: the Framingham study. Am J Med. 1977; 2:707-14.

  39. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An Updated coronary risk profile. A Statement for health profesionals. Circulation. 1991; 83:356-62.

  40. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospec-tive American studies. Circulation. 1989;79:8-15.

  41. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Effi-cacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005; 45:185-97. 32.

  42. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350:1505-15.

  43. Christopher J. Donnel O’, Elosua R. Factores de riesgo cardiovascular. Perspectivas derivadas del Fra-mingham Heart Study. Rev Esp Cardiol. 2008; 61:299-310.

  44. Instituto Nacional de Higiene, Epidemiología y Microbio-logía (INHEM). III Encuesta Nacional de Factores de Riesgo de Enfermedades Crónicas no Transmisibles en Cuba. Informe de Trabajo. La Habana: INHEM (CU); 2010.

  45. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Fram-ingham Heart Study. Circulation. 1983; 67:968-77.

  46. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kan-nel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162:1867-72.

  47. Eckel RH, Kahn R, Robertson RM, Rizza RA. Prevent-ing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the Amer- ican Heart Association. Diabetes Care. 2006; 29:1697-9.

  48. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hyperten-sion screening of 1 million Americans. JAMA. 1978; 240:1607-10.

  49. Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year followup of 227,000 Norwegian boys and girls. Am J Epidemiol. 2003; 157:517-23.

  50. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Bodymass index and mortality in Korean men and women. N Engl J Med. 2006;355:779-87

  51. Kannel WB, LeBauer EJ, Dawber TR, McNamara PM. Relation of body weight to developement of coronary heart disease. The Framingham Study. Circulation. 1967; 35:734-44.




2020     |     www.medigraphic.com